Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY2287411 in Mesothelin-Expressing Solid Tumors
NCT03507452Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2018
- Primary completion
- Sep 2021
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 5
01
Overview
Phase 1, open-label trial of Thorium-227 anetumab corixetan in mesothelioma, serous ovarian cancer and pancreatic ductal adenocarcinoma (PDAC) (4 cohorts), sponsored by Bayer. Primary endpoints: Dose-Limiting Toxicity at 6 weeks and Treatment-Emergent Adverse Events at 6 months. Started Jun 2018; status: completed.
02
Drugs
Thorium-227 anetumab corixetan
03
Conditions
mesotheliomaserous ovarian cancerpancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03507452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03507452.